"Nearly 10 billion state investment in sight, but afraid of the domestic pharmaceutical companies could not eat." A Beijing-based vaccine company's sales manager Li Wei (a pseudonym) in an interview with reporters exclaimed.
The end of October, China fever thermometer manufacturer the State Council promulgated the "vaccine supply system planning", in addition to the overall layout of good policy, investment in key projects have been identified as $ 9.4 billion. China baby thermometer manufacturer It seems many people in the industry, this figure is expected to have over "huge."
9.4 billion yuan will be who gets the still suspense.
Weak power of vaccines
"China is a truly great country vaccine, one large-scale production, the second is the market potential." Wei said, because of China's large population,China wrist blood pressure monitor the vaccine market has become a very large and full of potential "commercial Blue Ocean."
"This year a lot of good policies, can be described as the introduction of intensive, especially direct allocation of special funds and focus on investment approach,China forehead thermometer which greatly stimulated the bio-pharmaceutical industry, especially the enthusiasm of the vaccine industry." Wei said.
"This year,China electronic thermometer manufacturer Chinese vaccine company's growth rate will reach 20% by 2012, China's vaccine market will reach 12 billion yuan." Investment adviser in the pharmaceutical industry researcher Guo Li said. China medical thermometer However, with billion market size of "great power status" compared to the production of China's vaccine variety and quality was extremely weak. "Vaccines are still in the country are generic, self-developed varieties of very small, and from the target market, the domestic to the international vaccine market situation is also very few."
"If the World Health Organization pre-certified as an observation target, digital blood pressure monitor then China is no doubt behind." Guo Li said that as of 2010, has 24 companies by the World Health Organization certification, its vaccine products in the global circulation and China, digital thermometer manufacturer not any one company to obtain certification.
Opportunities and challenges of domestic pharmaceutical companies
"In recent years, bio-pharmaceutical industry to become venture a hit, the vaccine industry as the core of bio-pharmaceutical industry is scrambling to give money to first understand the glory."digital thermometer Said Li Wei, Hai Purui, Changchun Changsheng, Nanjing Kin Friends and so won the favor of foreign venture capital and venture capital.
But should not be overlooked is the development of China's vaccine industry there has always been difficult to make up the two short board. "First, lack of research capacity, especially in 6 kinds of hand, foot and mouth disease vaccine research and development. Second, the large-scale production and lack of emergency support capabilities, which have been fully reflected in the SARS incident out." China Pharmaceutical Group Corporation China Biotechnology (hereinafter referred to as "in the Health Group") Shen Liang, deputy general manager told reporters.
"In 2010, the Health Group R & D investment 382 million yuan, accounting for about 7% of sales volume, we plan to 'second five' during that ratio to 8% to 15%." Shen Liang said that the Health Group In addition to upgrading old products, development of combination vaccine, the supply side but also in the production of the production process and technology to promote innovation, such as the development of genetic engineering technology.
"Vaccine supply system construction plan," the announcement that planned immunization (EPI) to become a popular choice for the first benefit. "At present, China has already covered 15 kinds of EPI vaccines, but there is still a gap compared with developed countries, combined with matching funds over the number of different financial EPI, making some of the actual vaccination rate for EPI vaccines needs to be improved." Guo Li analysis.
EPI leader Tiantan Biological become the focus of concern. "Tiantan Biological is an important national immunization vaccine production base, part of 'team', and has just announced the completion of restructuring, its major shareholder is likely in the Health Group listed in Hong Kong.